LifeStance Health Group, Inc. (LFST) Stock Price & How to Invest

LifeStance Health Group runs outpatient mental healthcare at national scale. Founded in 2017 and public since June 2021, the company employs licensed therapists, psychologists, psychiatrists and psychiatric nurse practitioners through its subsidiaries and supported practices, then routes patients to them through in-network insurance relationships. Care is delivered both in person and virtually, from more than ~550 centers spread across ~33 states, and volume reached roughly ~2.6 million patient visits in the second quarter of 2026 alone. Unlike cash-pay teletherapy apps, LifeStance is built around commercial insurance: about ~88% of revenue comes from commercial payors, ~7% from government programs and ~4% from self-pay, which means reimbursement rates negotiated with health plans, not consumer subscription pricing, set the revenue line.

The financial story has flipped hard. Losses ran deep for years, with net losses of roughly ~$216M in 2022 and ~$186M in 2023 as the company absorbed acquisitions, real estate and stock compensation. Since then the model has scaled into its cost base: fiscal 2025 revenue of ~$1.42B produced the first full-year profit at ~$10M, and the trailing twelve months through June 2026 show ~$1.58B of revenue, ~$51M of net income and ~$174M of free cash flow. Second quarter 2026 revenue grew ~26% year over year with adjusted EBITDA nearly doubling to ~$66M, prompting management to raise full-year guidance to ~$1.685B to ~$1.725B of revenue. Investors are weighing that inflection against a valuation near ~92 times trailing earnings, concentrated payor exposure, and a sponsor base at TPG and Summit Partners still holding about ~35.4% of the stock.

Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. Valuation leaves little cushion, with the stock near ~92 times trailing earnings and ~36 times EV to EBITDA on a business whose GAAP net margin is about ~3%, meaning a growth deceleration toward the ~11% pace of 2025 would be poorly received. Legal and regulatory matters are ongoing rather than resolved: a privacy class action captioned Strong v. LifeStance Health Group, filed April 26, 2023 over the use of website pixel tracking technologies, is settling for roughly ~$3.0 million with a final approval hearing scheduled for October 2026, and the June 2021 IPO drew a securities class action in 2022 that is no longer disclosed as a pending matter in the company's Legal Proceedings item. Healthcare providers of this scale also carry standing exposure to fraud and abuse statutes, retroactive payor audits and state licensure rules across all ~33 states of operation. Financial leverage is moderate but real, with roughly ~$276M of term loan principal outstanding at SOFR plus ~3.00% maturing in December 2029 under a net leverage covenant, and TPG and Summit Partners together still hold about ~35.4% of the shares, an overhang that can weigh on the stock whenever those holders trim.

10 analysts publish price targets on LFST, averaging $12.90 against a $11.90 price as of August 2026, or +8.4%. The published targets run from $9.00 to $16.00, a moderate spread, and the ratings split 8 buy, 2 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LFST forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on LifeStance Health Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Clinician headcount plus productivity, compounding together. Revenue in this model is close to clinicians multiplied by visits multiplied by rate per visit. The most optimistic published target, $16.00, assumes this works close to its best case.

The case against. Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. The most pessimistic target, $9.00, is roughly what LFST is worth if this bites instead.

Read the full bull and bear case on LFST, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see LifeStance Health Group, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.58B, up ~20% year over year
• Net income (TTM): ~$51M, or ~$0.13 per share
• Adjusted EBITDA (Q2 2026): ~$66M, ~15.2% of revenue
• Free cash flow (TTM): ~$174M
• Market cap / enterprise value: ~$4.55B / ~$4.79B
• Valuation multiples: ~92x trailing earnings, ~3.1x sales, ~36x EV/EBITDA

Pricing reflects the inflection rather than the trailing profit. Full-year 2026 guidance of ~$215M to ~$235M in adjusted EBITDA against an enterprise value near ~$4.79B works out to roughly ~21x the midpoint, a very different figure from the ~92x trailing GAAP multiple, and the gap between those two numbers is essentially stock compensation, amortization and litigation costs added back. Cash of ~$226M against ~$276M of term loan principal leaves the balance sheet close to neutral.

Other names that sit close to LFST: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LFST exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LFST sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LFST fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

LifeStance has turned a long-unprofitable clinician roll-up into a business generating real cash, and the open question is whether ~26% revenue growth and mid-teens adjusted margins can hold long enough to justify a multiple that already prices in years of compounding.

Whether LFST is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LFST a buy or a sell?, and where the stock could go from here in the LFST stock forecast.

For income investors, whether LFST pays a dividend and how the payout looks is covered in does LFST pay a dividend? And to weigh LFST against a peer, read the full side-by-side comparisons: LFST vs ACHC and LFST vs TDOC.